What You Should Know:
- C2i Genomics, a cancer intelligence company launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore.
- The new clinical data will be presented at the 2022 American Association for Cancer Research (AACR) annual meeting in New Orleans,
Read More
Cancer Genomics
C2i Genomics, Twist Bioscience Partner to Develop Whole-Genome Cancer Reference Materials
What You Should Know:
- Today, Twist Bioscience and cancer genomics startup C2i Genomics announced a partnership to develop whole-genome cancer reference materials.
- This resource will provide diagnostic labs around the globe with the ability to better validate and monitor the quality of their whole-genome cancer screening and minimal residual disease (MRD) products for more accurate cancer detection.
C2i to integrate Twist’s library preparation kits into minimal residual
Read More
Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care
What You Should Know:
- Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop personalized treatment plans quickly and efficiently for their patients. See the full release
Read More
Why Cancer Registries are Part of America’s Fight for Racial Equality
According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white males. For some, those figures are staggering. For many others, they are reminders of the racial disparities that have existed for far too long in this country.
So, in 2020, when recent events have brought racial injustice back into the national
Read More
Personal Genome Diagnostics, Mayo Clinic Partner to Enhance Patient Care in Oncology
- Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications.- The shared vision and overall goal for PGDx and Mayo Clinic is to improve patient care by advancing the capabilities of oncology diagnostics testing. Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Mayo Clinic to enhance the development of clinical diagnostic solutions for
Read More
Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More
Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine
Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in
Read More
Celsius Therapeutics Launches with $65M to Develop Precision Therapeutics for Autoimmune Disease & Cancer
Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key
Read More
Why Did the Global Digital Health Market Strengthen During Q4 2017?
Healthcare innovation consultancy Enspektos, LLC, today released the latest edition of its quarterly study, digihealth impact trac. The report focuses on key Q4 2017 market themes and previews five digital health trends that will matter in 2018. The research reveals that telemedicine is having a far-reaching impact as adoption surges globally. Most importantly, telemedicine solutions are delivering economic benefits and re-shaping the patient-physician relationship, as clinicians learn what it
Read More
University of Michigan, Tempus Partner on Personalized Breast Cancer Medicine Initiative
Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. In 2017, it is estimated that more than 250,000 U.S. women will be diagnosed with new cases of invasive breast cancer. That’s why the University of Michigan Comprehensive Cancer Center has partnered with Tempus on a personalized cancer medicine initiative aimed providing most effective care for individuals diagnosed with breast cancer.As part of the initiative, Tempus will use
Read More
